The FDA approved updated Covid-19 vaccines from Pfizer, Moderna, and Novavax targeting the LP.8.1 subvariant for the 2025-26 season but limited their use to individuals at higher risk due to underlying conditions. This marks a shift from broader previous authorizations. Pfizer’s booster is approved for those aged 5-64 at high risk and for all adults over 65; Moderna’s for 6 months to 64 years similarly at risk, while Novavax is cleared for high-risk individuals 12 and older. The FDA has also rescinded emergency use authorizations for some prior Covid shots. HHS Secretary Robert F. Kennedy Jr. emphasized ending mandates while maintaining availability for vulnerable groups. The CDC currently recommends vaccines mainly for adults over 18, applying shared clinical decision-making for healthy children and pregnant women. The narrowed authorization suggests a more targeted booster strategy as the pandemic evolves.